Nippon Chemiphar Co., Ltd. (4539.T)
JPY 1489.0
(-0.4%)
JPY 1489.0
(-0.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -494 Million JPY | -104.98% |
| 2022 | -241 Million JPY | -129.21% |
| 2021 | 825 Million JPY | 46.28% |
| 2020 | 564 Million JPY | 54.95% |
| 2019 | 364 Million JPY | -75.14% |
| 2018 | 1.46 Billion JPY | -20.78% |
| 2017 | 1.84 Billion JPY | -34.84% |
| 2016 | 2.83 Billion JPY | -9.83% |
| 2015 | 3.14 Billion JPY | -4.26% |
| 2014 | 3.28 Billion JPY | -1.26% |
| 2013 | 3.32 Billion JPY | -14.1% |
| 2012 | 3.87 Billion JPY | 32.5% |
| 2011 | 2.92 Billion JPY | 46.22% |
| 2010 | 1.99 Billion JPY | 160.63% |
| 2009 | 767 Million JPY | 32.24% |
| 2008 | 580 Million JPY | -50.43% |
| 2007 | 1.17 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 74 Million JPY | 2366.67% |
| 2024 Q1 | 3 Million JPY | 100.66% |
| 2023 FY | -494 Million JPY | -104.98% |
| 2023 Q3 | 262 Million JPY | 236.46% |
| 2023 Q2 | -192 Million JPY | -81.13% |
| 2023 Q1 | -106 Million JPY | 75.52% |
| 2023 Q4 | -458 Million JPY | -274.81% |
| 2022 FY | -241 Million JPY | -129.21% |
| 2022 Q1 | 175 Million JPY | 163.87% |
| 2022 Q4 | -433 Million JPY | -1832.0% |
| 2022 Q2 | -8 Million JPY | -104.57% |
| 2022 Q3 | 25 Million JPY | 412.5% |
| 2021 Q4 | -274 Million JPY | -130.68% |
| 2021 Q1 | -26 Million JPY | -125.0% |
| 2021 Q2 | 232 Million JPY | 992.31% |
| 2021 Q3 | 893 Million JPY | 284.91% |
| 2021 FY | 825 Million JPY | 46.28% |
| 2020 Q3 | 649 Million JPY | 513.38% |
| 2020 Q4 | 104 Million JPY | -83.98% |
| 2020 FY | 564 Million JPY | 54.95% |
| 2020 Q1 | -32 Million JPY | 87.83% |
| 2020 Q2 | -157 Million JPY | -390.63% |
| 2019 Q1 | 666 Million JPY | 270.0% |
| 2019 FY | 364 Million JPY | -75.14% |
| 2019 Q2 | -47 Million JPY | -107.06% |
| 2019 Q3 | 8 Million JPY | 117.02% |
| 2019 Q4 | -263 Million JPY | -3387.5% |
| 2018 Q2 | 221 Million JPY | -49.08% |
| 2018 Q1 | 434 Million JPY | 1636.0% |
| 2018 Q4 | 180 Million JPY | -71.38% |
| 2018 FY | 1.46 Billion JPY | -20.78% |
| 2018 Q3 | 629 Million JPY | 184.62% |
| 2017 Q2 | 390 Million JPY | -33.79% |
| 2017 Q1 | 589 Million JPY | 8.67% |
| 2017 FY | 1.84 Billion JPY | -34.84% |
| 2017 Q4 | 25 Million JPY | -97.04% |
| 2017 Q3 | 844 Million JPY | 116.41% |
| 2016 Q2 | 536 Million JPY | -31.89% |
| 2016 Q4 | 542 Million JPY | -44.18% |
| 2016 FY | 2.83 Billion JPY | -9.83% |
| 2016 Q3 | 971 Million JPY | 81.16% |
| 2016 Q1 | 787 Million JPY | 13.4% |
| 2015 Q4 | 694 Million JPY | -37.31% |
| 2015 FY | 3.14 Billion JPY | -4.26% |
| 2015 Q3 | 1.1 Billion JPY | 46.43% |
| 2015 Q2 | 756 Million JPY | 28.57% |
| 2015 Q1 | 588 Million JPY | 45.19% |
| 2014 Q3 | 1.16 Billion JPY | 65.15% |
| 2014 Q4 | 405 Million JPY | -65.12% |
| 2014 FY | 3.28 Billion JPY | -1.26% |
| 2014 Q1 | 1.01 Billion JPY | 124.28% |
| 2014 Q2 | 703 Million JPY | -30.81% |
| 2013 Q3 | 1.21 Billion JPY | 52.07% |
| 2013 Q4 | 453 Million JPY | -62.72% |
| 2013 FY | 3.32 Billion JPY | -14.1% |
| 2013 Q1 | 860 Million JPY | 91.11% |
| 2013 Q2 | 799 Million JPY | -7.09% |
| 2012 Q3 | 1.1 Billion JPY | -4.08% |
| 2012 Q1 | 1.16 Billion JPY | 213.14% |
| 2012 Q4 | 450 Million JPY | -59.24% |
| 2012 FY | 3.87 Billion JPY | 32.5% |
| 2012 Q2 | 1.15 Billion JPY | -1.46% |
| 2011 Q2 | 579 Million JPY | -22.39% |
| 2011 Q3 | 1.22 Billion JPY | 111.57% |
| 2011 Q4 | 373 Million JPY | -69.55% |
| 2011 FY | 2.92 Billion JPY | 46.22% |
| 2011 Q1 | 746 Million JPY | 60.43% |
| 2010 FY | 1.99 Billion JPY | 160.63% |
| 2010 Q3 | 636 Million JPY | 18.66% |
| 2010 Q1 | 362 Million JPY | 158.57% |
| 2010 Q4 | 465 Million JPY | -26.89% |
| 2010 Q2 | 536 Million JPY | 48.07% |
| 2009 Q2 | 157 Million JPY | 28.69% |
| 2009 Q1 | 122 Million JPY | -32.6% |
| 2009 FY | 767 Million JPY | 32.24% |
| 2009 Q4 | 140 Million JPY | -59.77% |
| 2009 Q3 | 348 Million JPY | 121.66% |
| 2008 Q2 | 75 Million JPY | 0.0% |
| 2008 Q4 | 181 Million JPY | -40.85% |
| 2008 FY | 580 Million JPY | -50.43% |
| 2008 Q3 | 306 Million JPY | 308.0% |
| 2007 FY | 1.17 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 109.662% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 100.231% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 99.861% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 100.288% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | -152.671% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 101.574% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 105.193% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 100.925% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | 168.994% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 103.752% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 108.513% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | 125.153% |
| Tsumura & Co. | 20.01 Billion JPY | 102.468% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 112.298% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 109.809% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 102.799% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | 112.805% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 105.084% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | 108.216% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 83.956% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | 112.686% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | 39.138% |
| MedRx Co., Ltd | -933 Million JPY | 47.053% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 109.589% |
| Solasia Pharma K.K. | -1.13 Billion JPY | 56.629% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 79.156% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 107.6% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 102.616% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | 29.169% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 102.555% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 111.273% |